TY - JOUR AU - Druker, B. J. AU - Guilhot, F. AU - O’Brien, S. G. AU - Gathmann, I. AU - Kantarjian, H. AU - Gattermann, N. PY - 2006 DA - 2006// TI - Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia JO - N Engl J Med VL - 355 UR - https://doi.org/10.1056/NEJMoa062867 DO - 10.1056/NEJMoa062867 ID - Druker2006 ER - TY - JOUR AU - Simon, R. AU - Roychowdhury, S. PY - 2013 DA - 2013// TI - Implementing personalized cancer genomics in clinical trials JO - Nat Rev Drug Discov VL - 12 UR - https://doi.org/10.1038/nrd3979 DO - 10.1038/nrd3979 ID - Simon2013 ER - TY - JOUR AU - Gottesman, M. M. PY - 2002 DA - 2002// TI - Mechanisms of cancer drug resistance JO - Annu Rev Med VL - 53 UR - https://doi.org/10.1146/annurev.med.53.082901.103929 DO - 10.1146/annurev.med.53.082901.103929 ID - Gottesman2002 ER - TY - JOUR AU - Holohan, C. AU - Schaeybroeck, S. AU - Longley, D. B. AU - Johnston, P. G. PY - 2013 DA - 2013// TI - Cancer drug resistance: an evolving paradigm JO - Nat Rev Cancer VL - 13 UR - https://doi.org/10.1038/nrc3599 DO - 10.1038/nrc3599 ID - Holohan2013 ER - TY - JOUR AU - Trédan, O. AU - Galmarini, C. M. AU - Patel, K. AU - Tannock, I. F. PY - 2007 DA - 2007// TI - Drug resistance and the solid tumor microenvironment JO - J Natl Cancer Inst VL - 99 UR - https://doi.org/10.1093/jnci/djm135 DO - 10.1093/jnci/djm135 ID - Trédan2007 ER - TY - JOUR AU - Masters, J. R. PY - 2000 DA - 2000// TI - Human cancer cell lines: fact and fantasy JO - Nat Rev Mol Cell Biol VL - 1 UR - https://doi.org/10.1038/35043102 DO - 10.1038/35043102 ID - Masters2000 ER - TY - JOUR AU - Garnett, M. J. AU - Edelman, E. J. AU - Heidorn, S. J. AU - Greenman, C. D. AU - Dastur, A. AU - Lau, K. W. PY - 2012 DA - 2012// TI - Systematic identification of genomic markers of drug sensitivity in cancer cells JO - Nature VL - 483 UR - https://doi.org/10.1038/nature11005 DO - 10.1038/nature11005 ID - Garnett2012 ER - TY - JOUR AU - Barretina, J. AU - Caponigro, G. AU - Stransky, N. AU - Venkatesan, K. AU - Margolin, A. A. AU - Kim, S. PY - 2012 DA - 2012// TI - The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity JO - Nature VL - 483 UR - https://doi.org/10.1038/nature11003 DO - 10.1038/nature11003 ID - Barretina2012 ER - TY - JOUR AU - Seashore-Ludlow, B. AU - Rees, M. G. AU - Cheah, J. H. AU - Cokol, M. AU - Price, E. V. AU - Coletti, M. E. PY - 2015 DA - 2015// TI - Harnessing connectivity in a large-scale small-molecule sensitivity dataset JO - Cancer Discov VL - 5 UR - https://doi.org/10.1158/2159-8290.CD-15-0235 DO - 10.1158/2159-8290.CD-15-0235 ID - Seashore-Ludlow2015 ER - TY - JOUR AU - Rees, M. G. AU - Seashore-Ludlow, B. AU - Cheah, J. H. AU - Adams, D. J. AU - Price, E. V. AU - Gill, S. PY - 2016 DA - 2016// TI - Correlating chemical sensitivity and basal gene expression reveals mechanism of action JO - Nat Chem Biol VL - 12 UR - https://doi.org/10.1038/nchembio.1986 DO - 10.1038/nchembio.1986 ID - Rees2016 ER - TY - JOUR AU - Troyanskaya, O. AU - Cantor, M. AU - Sherlock, G. AU - Brown, P. AU - Hastie, T. AU - Tibshirani, R. PY - 2001 DA - 2001// TI - Missing value estimation methods for DNA microarrays JO - Bioinformatics VL - 17 UR - https://doi.org/10.1093/bioinformatics/17.6.520 DO - 10.1093/bioinformatics/17.6.520 ID - Troyanskaya2001 ER - TY - JOUR AU - Menden, M. P. AU - Iorio, F. AU - Garnett, M. AU - McDermott, U. AU - Benes, C. H. AU - Ballester, P. J. PY - 2013 DA - 2013// TI - Machine learning prediction of cancer cell sensitivity to drugs based on genomic and chemical properties JO - PLoS One VL - 8 UR - https://doi.org/10.1371/journal.pone.0061318 DO - 10.1371/journal.pone.0061318 ID - Menden2013 ER - TY - JOUR AU - Mitchison, T. J. PY - 2012 DA - 2012// TI - The proliferation rate paradox in antimitotic chemotherapy JO - Mol Biol Cell VL - 23 UR - https://doi.org/10.1091/mbc.E10-04-0335 DO - 10.1091/mbc.E10-04-0335 ID - Mitchison2012 ER - TY - JOUR AU - Savage, P. AU - Stebbing, J. AU - Bower, M. AU - Crook, T. PY - 2009 DA - 2009// TI - Why does cytotoxic chemotherapy cure only some cancers? JO - Nat Clin Pract Oncol VL - 6 UR - https://doi.org/10.1038/ncponc1260 DO - 10.1038/ncponc1260 ID - Savage2009 ER - TY - JOUR AU - Peetla, C. AU - Vijayaraghavalu, S. AU - Labhasetwar, V. PY - 2013 DA - 2013// TI - Biophysics of cell membrane lipids in cancer drug resistance: Implications for drug transport and drug delivery with nanoparticles JO - Adv Drug Deliv Rev VL - 65 UR - https://doi.org/10.1016/j.addr.2013.09.004 DO - 10.1016/j.addr.2013.09.004 ID - Peetla2013 ER - TY - JOUR AU - Waldman, Y. Y. AU - Geiger, T. AU - Ruppin, E. PY - 2013 DA - 2013// TI - A genome-wide systematic analysis reveals different and predictive proliferation expression signatures of cancerous vs. non-cancerous cells JO - PLoS Genet VL - 9 UR - https://doi.org/10.1371/journal.pgen.1003806 DO - 10.1371/journal.pgen.1003806 ID - Waldman2013 ER - TY - JOUR AU - Risso, D. AU - Ngai, J. AU - Speed, T. P. AU - Dudoit, S. PY - 2014 DA - 2014// TI - Normalization of RNA-seq data using factor analysis of control genes or samples JO - Nat Biotechnol VL - 32 UR - https://doi.org/10.1038/nbt.2931 DO - 10.1038/nbt.2931 ID - Risso2014 ER - TY - JOUR AU - Gagnon-Bartsch, J. A. AU - Speed, T. P. PY - 2012 DA - 2012// TI - Using control genes to correct for unwanted variation in microarray data JO - Biostatistics VL - 13 UR - https://doi.org/10.1093/biostatistics/kxr034 DO - 10.1093/biostatistics/kxr034 ID - Gagnon-Bartsch2012 ER - TY - JOUR AU - An, X. AU - Tiwari, A. K. AU - Sun, Y. AU - Ding, P. -. R. AU - Ashby, C. R. AU - Chen, Z. -. S. PY - 2010 DA - 2010// TI - BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review JO - Leuk Res VL - 34 UR - https://doi.org/10.1016/j.leukres.2010.04.016 DO - 10.1016/j.leukres.2010.04.016 ID - An2010 ER - TY - JOUR AU - Leo, A. AU - Gomez, H. L. AU - Aziz, Z. AU - Zvirbule, Z. AU - Bines, J. AU - Arbushites, M. C. PY - 2008 DA - 2008// TI - Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer JO - J Clin Oncol VL - 26 UR - https://doi.org/10.1200/JCO.2008.16.2578 DO - 10.1200/JCO.2008.16.2578 ID - Leo2008 ER - TY - JOUR AU - Bollag, G. AU - Tsai, J. AU - Zhang, J. AU - Zhang, C. AU - Ibrahim, P. AU - Nolop, K. PY - 2012 DA - 2012// TI - Vemurafenib: the first drug approved for BRAF-mutant cancer JO - Nat Rev Drug Discov VL - 11 UR - https://doi.org/10.1038/nrd3847 DO - 10.1038/nrd3847 ID - Bollag2012 ER - TY - JOUR AU - Barollo, S. AU - Bertazza, L. AU - Baldini, E. AU - Ulisse, S. AU - Cavedon, E. AU - Boscaro, M. PY - 2014 DA - 2014// TI - The combination of RAF265, SB590885, ZSTK474 on thyroid cancer cell lines deeply impact on proliferation and MAPK and PI3K/Akt signaling pathways JO - Invest New Drugs VL - 32 UR - https://doi.org/10.1007/s10637-014-0108-3 DO - 10.1007/s10637-014-0108-3 ID - Barollo2014 ER - TY - JOUR AU - Rocca, A. AU - Farolfi, A. AU - Bravaccini, S. AU - Schirone, A. AU - Amadori, D. PY - 2014 DA - 2014// TI - Palbociclib (PD 0332991): targeting the cell cycle machinery in breast cancer JO - Expert Opin Pharmacother VL - 15 UR - https://doi.org/10.1517/14656566.2014.870555 DO - 10.1517/14656566.2014.870555 ID - Rocca2014 ER - TY - STD TI - Finn RS. Harnessing Breakthroughs, Targeting Cures. AACR Anu Meet. 2014. http://webcast.aacr.org/p/2014annual/8685?utm_source=twitter&utm_medium=tweet&utm_content=finn&utm_campaign=2014am. Accessed 10 Jan 2015. UR - http://webcast.aacr.org/p/2014annual/8685?utm_source=twitter&utm_medium=tweet&utm_content=finn&utm_campaign=2014am ID - ref24 ER - TY - JOUR AU - DeMichele, A. AU - Clark, A. AU - Tan, K. S. AU - Heitjan, D. F. AU - Gramlich, K. AU - Gallagher, M. PY - 2015 DA - 2015// TI - CDK 4/6 inhibitor Palbociclib (PD0332991) in Rb + advanced breast cancer: phase ii activity, safety and predictive biomarker assessment JO - Clin Cancer Res VL - 21 UR - https://doi.org/10.1158/1078-0432.CCR-14-2258 DO - 10.1158/1078-0432.CCR-14-2258 ID - DeMichele2015 ER - TY - JOUR AU - Brenner, J. C. AU - Feng, F. Y. AU - Han, S. AU - Patel, S. AU - Goyal, S. V. AU - Bou-Maroun, L. M. PY - 2012 DA - 2012// TI - PARP-1 inhibition as a targeted strategy to treat Ewing’s sarcoma JO - Cancer Res VL - 72 UR - https://doi.org/10.1158/0008-5472.CAN-11-3648 DO - 10.1158/0008-5472.CAN-11-3648 ID - Brenner2012 ER - TY - JOUR AU - Choy, E. AU - Butrynski, J. E. AU - Harmon, D. C. AU - Morgan, J. A. AU - George, S. AU - Wagner, A. J. PY - 2014 DA - 2014// TI - Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy JO - BMC Cancer VL - 14 UR - https://doi.org/10.1186/1471-2407-14-813 DO - 10.1186/1471-2407-14-813 ID - Choy2014 ER - TY - JOUR AU - Rodon, J. AU - DeSantos, V. AU - Ferry, R. J. AU - Kurzrock, R. PY - 2008 DA - 2008// TI - Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials JO - Mol Cancer Ther VL - 7 UR - https://doi.org/10.1158/1535-7163.MCT-08-0265 DO - 10.1158/1535-7163.MCT-08-0265 ID - Rodon2008 ER - TY - JOUR AU - Prinz, F. AU - Schlange, T. AU - Asadullah, K. PY - 2011 DA - 2011// TI - Believe it or not: how much can we rely on published data on potential drug targets? JO - Nat Rev Drug Discov VL - 10 UR - https://doi.org/10.1038/nrd3439-c1 DO - 10.1038/nrd3439-c1 ID - Prinz2011 ER - TY - JOUR AU - Czarnecka, A. M. AU - Oborska, S. AU - Rzepecki, P. AU - Szczylik, C. PY - 2015 DA - 2015// TI - Development of chronic myeloid leukaemia in patients treated with anti-VEGF therapies for clear cell renal cell cancer JO - Future Oncol VL - 11 UR - https://doi.org/10.2217/fon.14.135 DO - 10.2217/fon.14.135 ID - Czarnecka2015 ER - TY - STD TI - Phase II, two-stage, two-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer (EC). 2013 ASCO Annual Meeting. http://meetinglibrary.asco.org/content/112592-132. Accessed 15 Sep 2015. UR - http://meetinglibrary.asco.org/content/112592-132 ID - ref31 ER - TY - JOUR AU - Haigis, K. M. AU - Kendall, K. R. AU - Wang, Y. AU - Cheung, A. AU - Haigis, M. C. AU - Glickman, J. N. PY - 2008 DA - 2008// TI - Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon JO - Nat Genet VL - 40 UR - https://doi.org/10.1038/ng.115 DO - 10.1038/ng.115 ID - Haigis2008 ER - TY - JOUR AU - Nakayama, N. AU - Nakayama, K. AU - Yeasmin, S. AU - Ishibashi, M. AU - Katagiri, A. AU - Iida, K. PY - 2008 DA - 2008// TI - KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer JO - Br J Cancer VL - 99 UR - https://doi.org/10.1038/sj.bjc.6604783 DO - 10.1038/sj.bjc.6604783 ID - Nakayama2008 ER - TY - JOUR AU - Yu, W. AU - He, X. AU - Ni, Y. AU - Ngeow, J. AU - Eng, C. PY - 2015 DA - 2015// TI - Cowden syndrome-associated germline SDHD variants alter PTEN nuclear translocation through SRC-induced PTEN oxidation JO - Hum Mol Genet VL - 24 UR - https://doi.org/10.1093/hmg/ddu425 DO - 10.1093/hmg/ddu425 ID - Yu2015 ER - TY - STD TI - Phase II study of the MEK inhibitor refametinib (BAY 86-9766) in combination with gemcitabine in patients with unresectable, locally advanced, or metastatic pancreatic cancer: Biomarker results. 2014 ASCO Annual Meeting. http://meetinglibrary.asco.org/content/130837-144. Accessed 24 Sep 2015. UR - http://meetinglibrary.asco.org/content/130837-144 ID - ref35 ER - TY - JOUR AU - Haibe-Kains, B. AU - El-Hachem, N. AU - Birkbak, N. J. AU - Jin, A. C. AU - Beck, A. H. AU - Aerts, H. J. W. L. PY - 2013 DA - 2013// TI - Inconsistency in large pharmacogenomic studies JO - Nature VL - 504 UR - https://doi.org/10.1038/nature12831 DO - 10.1038/nature12831 ID - Haibe-Kains2013 ER - TY - JOUR PY - 2015 DA - 2015// TI - The Genomics of Drug Sensitivity in Cancer Consortium. Pharmacogenomic agreement between two cancer cell line data sets JO - Nature VL - 528 ID - ref37 ER - TY - JOUR AU - Hafner, M. AU - Niepel, M. AU - Chung, M. AU - Sorger, P. K. PY - 2016 DA - 2016// TI - Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs JO - Nat Methods VL - 13 UR - https://doi.org/10.1038/nmeth.3853 DO - 10.1038/nmeth.3853 ID - Hafner2016 ER - TY - STD TI - Friedman J, Hastie T, Simon N, Maintainer RT. Package “glmnet” Title Lasso and Elastic-Net Regularized Generalized Linear Models. 2016. http://www.jstatsoft.org/v33/i01/. Accessed 2 Aug 2016. UR - http://www.jstatsoft.org/v33/i01/ ID - ref39 ER - TY - JOUR AU - Irizarry, R. A. AU - Hobbs, B. AU - Collin, F. AU - Beazer-Barclay, Y. D. AU - Antonellis, K. J. AU - Scherf, U. PY - 2003 DA - 2003// TI - Exploration, normalization, and summaries of high density oligonucleotide array probe level data JO - Biostatistics VL - 4 UR - https://doi.org/10.1093/biostatistics/4.2.249 DO - 10.1093/biostatistics/4.2.249 ID - Irizarry2003 ER - TY - JOUR AU - Dai, M. AU - Wang, P. AU - Boyd, A. D. AU - Kostov, G. AU - Athey, B. AU - Jones, E. G. PY - 2005 DA - 2005// TI - Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data JO - Nucleic Acids Res VL - 33 UR - https://doi.org/10.1093/nar/gni179 DO - 10.1093/nar/gni179 ID - Dai2005 ER - TY - JOUR AU - Subramanian, A. AU - Tamayo, P. AU - Mootha, V. K. AU - Mukherjee, S. AU - Ebert, B. L. AU - Gillette, M. A. PY - 2005 DA - 2005// TI - Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles JO - Proc Natl Acad Sci U S A VL - 102 UR - https://doi.org/10.1073/pnas.0506580102 DO - 10.1073/pnas.0506580102 ID - Subramanian2005 ER -